Palo Santo
Palo Santo, founded in 2020 and based in Chicago, Illinois, is a venture capital firm focused on advancing mental wellness through strategic investments. The company targets opportunities within sectors such as drug discovery and development, digital health solutions, and therapeutic services. With a commitment to addressing pressing mental health challenges, Palo Santo aims to support the development of clinically effective, affordable treatments for conditions like depression, PTSD, and addiction. The firm recognizes the fragmentation in the emerging ecosystem of mental health solutions and seeks to capitalize on high growth potential within biotech and healthcare. By backing passionate and ethical management teams, Palo Santo is positioned to play a vital role in transforming mental health care and improving access to innovative treatment options.
13 past transactions
Psylo
Seed Round in 2024
Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.
Reunion Neuroscience
Series A in 2024
Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company’s primary focus is on its lead asset, RE104, a proprietary serotonergic psychedelic compound designed as a fast-acting and durable antidepressant for patients experiencing postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which comprises compounds aimed at achieving more selective serotonin receptor activity with reduced psychoactivity, thereby broadening the potential applications for chronic treatment scenarios. The company seeks to address significant gaps in mental health care through innovative pharmacological approaches.
Journey Clinical
Series A in 2023
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Gilgamesh Pharmaceuticals
Series B in 2022
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.
Sensorium Therapeutics
Venture Round in 2022
Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.
Kadence Bio
Convertible Note in 2022
Kadence Bio is a clinical-stage life sciences company developing novel therapeutics, with a focus on small molecule programs addressing sexual and mental well-being. Its lead compound KH-001 is being developed as a treatment for premature ejaculation, reflecting the company’s aim to provide additional options for patients and expand therapeutic opportunities in areas with significant unmet need.
Fluence
Seed Round in 2021
Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.
Wavepaths
Seed Round in 2021
Wavepaths, established in 2018 and based in London, specializes in developing accessible technology for psychedelic therapy. The company creates personalized soundtracks using intelligent technologies and immersive media, aiming to facilitate inner exploration and emotional reconnection during drug-free therapeutic sessions. Their offerings span the fields of information technology, healthcare, and personal health.
Delix Therapeutics
Series A in 2021
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.
Journey Clinical
Seed Round in 2021
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Beckley Psytech
Series B in 2021
Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.
Ksana Health
Seed Round in 2021
Ksana Health, founded in 2019 and based in Eugene, Oregon, is a developer of a digital mental health platform that aims to enhance mental health outcomes through personalized behavioral insights and timely interventions. The company's platform enables the collection of mental health data from users, which is then seamlessly transferred to healthcare practitioners via an app. By providing passive and continuous remote patient monitoring alongside digital therapeutics, Ksana Health seeks to support individuals in managing their mental health effectively.
Eleusis
Series A in 2020
Eleusis is a clinical stage life science company focused on harnessing the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics. The company aims to develop innovative psychedelic drug therapies that address unmet medical needs, particularly in the field of psychiatry and beyond. Eleusis is advancing a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. By doing so, the company seeks to provide healthcare providers and pharmaceutical companies with viable alternatives to conventional therapies, thereby broadening the scope of treatment options available to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.